With box warnings

Without box warnings

Branded

Generic

4 results

daliresp
(roflumilast)
AstraZeneca Pharmaceuticals LP
Usage: DALIRESP® is indicated for reducing the risk of COPD exacerbations in patients with severe COPD linked to chronic bronchitis and a history of exacerbations. It is not a bronchodilator and should not be used for acute bronchospasm relief. The initial dose is 250 mcg for the first four weeks only.
eucrisa
(crisaborole)
Pfizer Laboratories Div Pfizer Inc
Usage: EUCRISA is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients aged 3 months and older.
otezla
(apremilast)
Amgen Inc
Usage: OTEZLA is indicated for treating adult patients with active psoriatic arthritis, adults and pediatric patients (ages 6+, ≥20 kg) with moderate to severe plaque psoriasis, and adults with oral ulcers associated with Behçet's Disease.
roflumilast
(Roflumilast)
MAJOR PHARMACEUTICALS
Usage: Roflumilast Tablets are indicated for reducing COPD exacerbation risk in patients with severe COPD and chronic bronchitis. It is not a bronchodilator and is not intended for acute bronchospasm relief. The starting dose is 250 mcg for the first four weeks and is not the therapeutic dose.

Phosphodiesterase 4 Inhibitor class drugs

daliresp